FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included
US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China...
Company
Waterdrop Integrates DeepSeek AI to Boost Insurance Ecosystem
China-based Waterdrop Inc. (NYSE: WDH), a crowdfunding-based health insurance platform, announced a strategic integration with...
Boehringer Ingelheim Launches LENTICLAIR Study for CF Gene Therapy BI 3720931
German pharmaceutical company Boehringer Ingelheim announced the initiation of the Phase I/II LENTICLAIR study for...
Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...
Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Innogen Pharmaceutical Launches Efsubaglutide Alfa for Type 2 Diabetes in China
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, announced the...
Bayer’s AskBio Receives RMAT Designation for AB-1005 in Parkinson’s Disease
German pharmaceutical giant Bayer (ETR: BAYN) announced that its gene therapy subsidiary AskBio Inc. has...
Phanes Therapeutics Doses First Patient in Peluntamig Study for SCLC and NEC
Sino-US biotech Phanes Therapeutics Inc. announced that the first patient has been dosed in a...
Epitopea and Merck Partner to Identify Cryptigen Tumor Antigens
UK-based RNA immunotherapy developer Epitopea announced a licensing and research cooperation agreement with US pharmaceutical...
Boehringer Ingelheim’s Zongertinib NDA Accepted by FDA for HER2-Mutated NSCLC
Germany-based Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has accepted its...
Hepalink Pharmaceutical’s H1710 Heparanase Inhibitor Approved for Phase I Study
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that it has received approval...
Henlius Biotech’s Avastin Biosimilar Hanbeitai Approved in Bolivia
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that its biosimilar of Roche’s Avastin (bevacizumab), Hanbeitai,...
Astellas Pharma’s Xospata Wins Regular NMPA Approval for FLT3-Mutated AML
Japan-based Astellas Pharma Inc. (TYO: 4503, OTCMKTS: ALPMY ) announced that the National Medical Products...
Hanx Biopharmaceuticals’ HX009 Receives NMPA Clearance for TNBC Study
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clearance from the National Medical...
Huadong Medicine’s MediBeacon TGFR System Approved by NMPA for GFR Measurement
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received marketing approval from...
Sunshine Guojian and Shenyang 3SBio License 612 and 708 Programs for Anti-Tumor Development
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd and Shenyang 3SBio Co., Ltd, both subsidiaries of...
Antengene to Boost T Cell Engager Platform with AI Investment and DeepSeek Deployment
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced plans to increase investment in establishing a...
Jiangxi Rimag Group and Xunfei Healthcare Form Strategic Alliance for Smart Healthcare
China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) announced a strategic alliance with Xunfei Healthcare...
Rendu Biotechnology Partners with Green Apple Medical System for RNA Diagnostics Expansion
Rendu Biotechnology Co., Ltd., (SHA: 688193) a Shanghai-based specialist in RNA molecular diagnostics, has entered...
Genuine Biotech Files for Hong Kong IPO with Azvudine and ZS-1003 in Pipeline
China-based Genuine Biotech Limited has filed for an initial public offering (IPO) on the Hong...